Recent developments include a $14 million private placement, preliminary Q4 2025 revenue reporting, ongoing FDA submissions for AI-assisted modules, and preparations for the CapsoCam Colon second-generation 510(k) submission.

• CapsoVision announced a Q4 2025 earnings conference call scheduled for March 26, 2026 [N1].
• The company closed a $14 million private placement and reported preliminary Q4 2025 revenue of $3.9 million [N2].
• CapsoVision submitted an FDA 510(k) application for its AI-assisted module in CapsoCam Plus in early 2026 [N7].
• The company is seeking FDA clearance for AI-powered reading in CapsoCam Plus, with submissions ongoing [N8].
• Enrollment for the second arm pivotal study of the second-generation CapsoCam Colon capsule has exceeded 500 patients, with FDA 510(k) submission planned for Q3 2026 [S1].

CapsoVision’s growth potential is supported by increasing adoption of its CapsoCam Plus capsule, demonstrated by 15% revenue growth in 2025 and expanding international sales. The company’s AI-assisted pathology detection technology, pending FDA clearance, could reduce clinician review time and improve diagnostic yield, enhancing product attractiveness. The development of the CapsoCam Colon capsule with AI and 3D sensing may expand the company’s addressable market into colorectal cancer screening and surveillance. Telemedicine-enabled remote ingestion and cloud-based workflows align with healthcare trends toward convenience and scalability. The company’s ongoing clinical studies and regulatory submissions represent key milestones toward product expansion and revenue diversification.

CapsoVision faces significant risks including regulatory delays or failure to obtain FDA 510(k) clearances for its AI modules and CapsoCam Colon capsule, which could delay or prevent commercialization and revenue growth. The company has a history of net losses and substantial doubt about its ability to continue as a going concern without additional financing, which may not be available on favorable terms. Supply chain dependencies on single-source suppliers in Asia expose the company to geopolitical, trade, and natural disaster risks that could disrupt manufacturing and delivery. Competitive pressures from larger, better-resourced companies with established brand recognition may limit market penetration. The company’s ability to expand indications and achieve broad adoption of new products is uncertain and subject to clinical and regulatory challenges.

CapsoVision’s competitive moat is built on its proprietary 360° panoramic capsule technology, which provides a more complete and unobstructed view of the GI tract compared to competitors’ end-view capsules. The integration of AI-assisted pathology detection and 3D polyp measurement technology enhances diagnostic accuracy and clinical utility. The company’s cloud-based platform enables telemedicine and remote video review, improving clinical workflow and patient convenience. Its extensive patent portfolio of over 140 issued patents protects key aspects of its capsule design and technology. Long-standing relationships with single-source suppliers provide manufacturing advantages, though also introduce supply chain risks. These factors collectively create barriers to entry and differentiate CapsoVision’s offerings in the capsule endoscopy market.

• Regulatory Approval Risks: Delays or failure to obtain FDA 510(k) clearances for AI-assisted modules and CapsoCam Colon capsules could adversely impact commercialization and revenue growth.
• Financial and Going Concern Risks: The company has a history of net losses, substantial accumulated deficit, and disclosed substantial doubt about its ability to continue as a going concern without additional financing.
• Supply Chain Risks: Dependence on single-source suppliers in Taiwan and Japan exposes the company to geopolitical tensions, trade restrictions, and natural disasters that could disrupt manufacturing and supply.
• Competitive Risks: Competition from larger companies with greater resources and brand recognition may limit CapsoVision’s market share and pricing power.
• Market Adoption Risks: Broad adoption of new products like CapsoCam Colon depends on expanding indications, improving accuracy, and achieving satisfactory completion rates, which are uncertain.

• CapsoVision, Inc is a global commercial-stage medical technology company focused on diagnostic and screening products for abnormalities of the gastrointestinal (GI) tract, headquartered in Saratoga, California, incorporated in 2005.
• The company’s core product is the CapsoCam capsule endoscopy system, including the CapsoCam Plus capsule for small bowel visualization and associated software CapsoCloud and CapsoView.
• CapsoCam Plus provides a 360° panoramic video of the small bowel mucosa, capturing images with four cameras and storing video onboard the capsule, enabling zero-capex, wire-free data collection.
• CapsoCam Plus received FDA 510(k) clearance in 2016, with a pediatric indication (children aged 2 and above) and telemedicine remote ingestion clearance added in December 2024.
• As of December 31, 2025, CapsoCam Plus has been used in over 161,000 patients, generating approximately $13.6 million in revenue for 2025, a 15% increase over 2024.
• International sales accounted for 21% of total revenue in 2025, with major markets including France, Germany, and Canada.
• The company is developing an AI-assisted pathology detection module for CapsoCam Plus, with FDA 510(k) submission made in December 2025 and anticipated FDA clearance targeted by mid-2026.
• CapsoVision is developing a capsule delivery device and a patency capsule, with commercialization and FDA submission planned in 2026.
• The company is developing the CapsoCam Colon capsule endoscopy system for colon visualization and polyp detection, incorporating AI for automated polyp detection and 3D sensing for polyp size measurement.
• The first-generation CapsoCam Colon 510(k) submission was discontinued after FDA feedback; the company is focusing on a second-generation product with improved imaging and AI, with a pivotal study enrolling over 500 patients and 510(k) submission expected in Q3 2026.
• CapsoCam Colon is intended for patients with incomplete colonoscopy or GI bleeding risks and aims to expand indications to broader colorectal cancer screening populations.
• The company’s revenue growth to date is primarily from CapsoCam Plus sales; CapsoCam Colon-related revenues are not expected until after FDA clearance, anticipated in late 2026 or later.
• CapsoVision has over 140 issued patents covering its capsule and technology as of December 31, 2025.
• Manufacturing relies on single-source suppliers in Asia, including lens modules from Largan (Taiwan), CMOS image sensors from Toshiba (Japan), and ASICs from Moai/Speedbridge (Taiwan).
• Supply chain risks include geopolitical tensions in Asia, natural disasters, and single-source supplier dependencies.
• The company’s 2025 net loss was $25.3 million with an accumulated deficit of $155.7 million as of December 31, 2025.
• Cash and cash equivalents were approximately $10.1 million at year-end 2025, with a current ratio of 3.77, indicating liquidity from current assets over current liabilities.
• The company completed a $23.4 million IPO in July 2025 and a $14 million private placement in March 2026 to support operations and development.
• CapsoVision’s 2025 revenue was $13.6 million, up 15% from 2024, driven by increased capsule sales and service offerings.
• The company faces substantial doubt about its ability to continue as a going concern without additional financing, as disclosed in its 2024 and 2025 financial statements.
• Risks include regulatory delays or failure to obtain FDA 510(k) clearances for AI modules and CapsoCam Colon, competitive pressures from larger companies, supply chain disruptions, and the need for additional capital.
• The company sells primarily to gastroenterologists in clinics and hospitals, using a direct sales model in the U.S. and distributors internationally, with approximately 90% customer retention in 2025.
• CapsoVision’s cloud-based platform CapsoCloud enables remote video streaming and review, supporting telemedicine and flexible clinical workflows.
• The company is conducting feasibility studies for new indications including pancreatic cancer detection and esophageal varices screening, subject to funding and clinical priorities.
• The company’s operating expenses increased in 2025 due to higher R&D, selling and marketing, and general administrative costs associated with public company status and product development.
• CapsoVision’s clinical development includes ongoing pivotal studies for CapsoCam Colon and AI-assisted pathology detection tools, with regulatory submissions planned in 2026.
• The company’s business model includes product sales, software-as-a-service offerings, and reading services, with revenue recognized at point of sale or over time for cloud services.
• The company has agreements with group purchasing organizations (GPOs) that affect pricing and sales terms with hospital and clinic members.
• CapsoVision’s competitive advantages include its 360° panoramic capsule design, AI-assisted detection, telemedicine-enabled workflow, and 3D polyp measurement technology.